AI-based prognosis and chemotherapy benefit in node-positive, HR+ breast cancer: a blinded external validation on SWOG-8814 trial
Source check: Source checked. Not independent scientific confirmation.
Finding: Results/Abstract: in the multi-modal score, DFS association HR 1.60 (95% CI 1.44–1.78) and C-index 0.66 versus 0.59 for histology-only. Chemotherapy-benefit interaction was exploratory and did not meet conventional significance (p=0.053); only the prognostic result supports approval. This is the result-bearing preprint version dated 2026-10-23; peer-review status is not established by the reviewed source.
Technology: Methods/Abstract: locked Ataraxis Breast CTX scores use H&E whole-slide pathology alone or combined with clinical variables; trial data were not used for retraining and predictions were blinded to outcome.
Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Methods/Abstract: locked Ataraxis Breast CTX scores use H&E whole-slide pathology alone or combined with clinical variables; trial data were not used for retraining and predictions were blinded to outcome.
- Test and result
- Results/Abstract: in the multi-modal score, DFS association HR 1.60 (95% CI 1.44–1.78) and C-index 0.66 versus 0.59 for histology-only. Chemotherapy-benefit interaction was exploratory and did not meet conventional significance (p=0.053); only the prognostic result supports approval. Methods, “Study design and population”: blinded external evaluation in 677 of 1,477 participants from phase III randomized SWOG-8814, with outcome analysis by SWOG; DFS primary endpoint. The 677-sample digitized-slide subset is 46% of trial cohort; not prospective contemporary clinical utility.
- Limitation / still unknown
- nostic association with DFS in a blinded external randomized-trial cohort; chemotherapy-benefit prediction remains exploratory and unconfirmed.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.medrxiv.org/content/10.64898/2026.10.21.26366092v1.full.pdf · https://www.medrxiv.org/content/10.64898/2026.10.21.26366092v1.full · https://pmc.ncbi.nlm.nih.gov/articles/PMC13738861/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.